HiFect? is amaxa GmbH's newly developed biochemical transfection reagent for standard cell lines.
amaxa's CEO Rainer Christine explains that "HiFect provides high transfection efficiencies for a wide variety of adherent cell lines, while displaying only minor cytotoxic effects on the cells, e.g. 98% transfection efficiency and 77% viability in CHO-K1 cells."
HiFect is the optimal cost effective addition to the well established Nucleofector technology, the best system for gene transfer into difficult-to-transfect cell lines and primary cells.
Product directory
